PolyPid's D-PLEX 100 Hits Endpoints in Phase 3 SHIELD II Trial
Ticker: PYPD · Form: 6-K · Filed: Jun 9, 2025 · CIK: 1611842
| Field | Detail |
|---|---|
| Company | Polypid Ltd. (PYPD) |
| Form Type | 6-K |
| Filed Date | Jun 9, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial-results, drug-development, medical-devices
TL;DR
PolyPid's D-PLEX 100 shows strong Phase 3 results, reducing surgical infections - big win!
AI Summary
PolyPid Ltd. announced positive topline results on June 9, 2025, from its Phase 3 SHIELD II trial for D-PLEX 100. The study demonstrated a significant reduction in surgical site infections and successfully met its primary and all key secondary endpoints.
Why It Matters
Positive trial results for D-PLEX 100 could lead to regulatory approval, potentially offering a new solution to reduce surgical site infections, a common and costly complication.
Risk Assessment
Risk Level: medium — While results are positive, regulatory approval and market adoption are still uncertain, and the company's financial health remains a factor.
Key Players & Entities
- PolyPid Ltd. (company) — Registrant
- D-PLEX 100 (product) — Drug candidate
- Phase 3 SHIELD II trial (trial) — Clinical study
- June 9, 2025 (date) — Announcement date
FAQ
What is the primary purpose of the D-PLEX 100 drug candidate?
The D-PLEX 100 drug candidate is being studied for its ability to reduce surgical site infections.
What were the main outcomes of the Phase 3 SHIELD II trial?
The trial demonstrated a significant reduction in surgical site infections and successfully met its primary and all key secondary endpoints.
When did PolyPid Ltd. announce these results?
PolyPid Ltd. announced the topline results on June 9, 2025.
What form was filed with the SEC regarding this announcement?
A Form 6-K was filed, incorporating a press release dated June 9, 2025.
What is the company's principal executive office address?
The company's principal executive office is located at 18 Hasivim Street, Petach Tikva 495376, Israel.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 9, 2025 regarding PolyPid Ltd. (PYPD).